Posted by Michael Wonder on 09 May 2026
Vertex announces Casgevy reimbursement agreement for the treatment of sickle cell disease and transfusion-dependent beta thalassaemia in Germany
6 May 2026 - The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany.
Vertex Pharmaceuticals announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel).
This agreement secures sustainable access to this innovative one time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassaemia.
